Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis

MLA

Moi, Laura, et al. “Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis.” Journal of Thoracic Oncology, vol. 16, no. 2, Feb. 2021, pp. 318–26. EBSCOhost, https://doi.org/10.1016/j.jtho.2020.09.007.

APA

Moi, L., Bouchaab, H., Mederos, N., Nguyen-Ngoc, T., Perreau, M., Fenwick, C., Vaucher, J., Sempoux, C., Peters, S., & Obeid, M. (2021). Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis. Journal of Thoracic Oncology, 16(2), 318–326. https://doi.org/10.1016/j.jtho.2020.09.007

Chicago

Moi, Laura, Hasna Bouchaab, Nuria Mederos, Tu Nguyen-Ngoc, Matthieu Perreau, Craig Fenwick, Julien Vaucher, Christine Sempoux, Solange Peters, and Michel Obeid. 2021. “Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis.” Journal of Thoracic Oncology 16 (2): 318–26. doi:10.1016/j.jtho.2020.09.007.